カテゴリ： GlobalData, アイルランド, 企業調査

Allergan Plc (AGN)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Allergan Plc (AGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012262
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：427
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アイルランド
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Allergan Plc (Allergan) is a specialty pharmaceutical company that develops and sells branded pharmaceuticals, biosimilar and over-the-counter (OTC) pharmaceutical products. It offers products in the areas of eye care, medical aesthetics, dermatology, central nervous system, gastroenterology, women’s health, urology and anti-infective therapeutic categories. The company sells its products to retailers, drug wholesalers and distributors, including national retail drug and food store chains, mail order retailers, hospitals, clinics, government agencies and managed healthcare providers such as health maintenance organizations and other institutions. It has operations in several countries across the Americas, Europe, Asia-Pacific, the Middle East and Africa. Allergan is headquartered in Dublin, Ireland.

Allergan Plc (AGN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 10
List of Figures 14
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 15
Allergan Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 16
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 17
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 18
Allergan Plc, Medical Devices Deals, 2011 to YTD 2017 20
Allergan Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 21
Allergan Plc, Pharmaceuticals & Healthcare, Deal Details 35
Asset Purchase 35
Allergan Acquires Rights to LiRIS from TARIS Biomedical for USD588 Million 35
Actavis Acquires Four Generic Products From Akorn And Hi-Tech Pharmacal 36
Actavis Acquires Worldwide Rights To Albaconazole From Palau Pharma 38
Actavis Acquires Worldwide Rights To Metronidazole 1.3% Vaginal Gel From Valeant Pharma For US$55 Million 39
Furiex Pharma Acquires Priligy From Janssen Pharmaceutica And Alza 40
Watson Pharma Acquires Generic Pharma Products From Perrigo 41
Forest Labs Acquires Worldwide Rights Of Azimilide From Blue Ash Therapeutics 42
Allergan Acquires Distribution Business from Genop Healthcare 43
Venture Financing 44
Chase Pharma Raises USD12 Million in Financing Round 44
Chase Pharma Raises Additional USD0.5 Million in Venture Financing 45
Akarna Therapeutics Raises USD15 Million in Series B Financing 46
Rhythm Pharma Raises Additional USD15 Million in Series A Financing Round 47
RetroSense Therapeutics Raises USD6 Million in Series B Financing Round 48
Chase Pharma Raises USD3 Million in Venture Financing 49
RetroSense Therapeutics Raises USD6 Million in Series A Financing 50
Naurex Raises USD80 Million in Series C Venture Financing 51
Colorescience Raises USD15 Million in Series B Venture Financing 53
Chase Pharma Raises USD21 Million in Series B Financing 54
Naurex Raises US$25 Million In Venture Financing 55
Topokine Therapeutics Raises Funds Through Venture Financing 57
Rhythm Holding Raises US$11 Million In Venture Financing 58
Colorescience Raises US$10 Million In Series A Financing 59
Anterios Raises US$8.5 Million In Venture Financing 60
Anterios Raises US$4.7 Million In Venture Financing 61
Topokine Therapeutics Raises Funds Through Venture Financing 62
Colorescience Raises US$15 Million In Venture Financing 63
Regado Biosciences Raises US$51 Million In Series E Financing 64
Naurex Raises US$38 Million In Series B Financing 66
Rhythm Pharma Raises US$33 Million In Series B Financing 68
Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 70
Rhythm Pharma Raises US$9.5 Million In Venture Financing 71
Uteron Pharma Raises US$10.4 Million In Venture Financing 72
Regado Biosciences Raises US$6.8 Million In Venture Financing 73
Motus Therapeutics Secures USD25 Million in Series B Round of Venture Funding 74
Uteron Pharma Raises US$19 Million In Venture Financing 75
SkinMedica Raises US$16.8 Million In Venture Financing 76
KYTHERA BioPharma Secures US$37.42 Million In Series D Financing Round 77
Anterios Secures US$3.1 Million In Venture Financing 79
Regado Biosciences Secures US$11.6 Million In Financing 80
Naurex Secures US$18 Million In Series A Financing Round 81
RetroSense Therapeutics Secures US$0.07 Million In Venture Financing 83
Chase Pharma Secures US$1.2 Million In Venture Financing 84
Private Equity 85
TPG Capital Acquires Aptalis Pharma from Actavis 85
VMG Partners Invests In Colorescience 86
SRIW Invests US$2 Million In Uteron Pharma 87
Partnerships 88
Lyndra Enters into Agreement with Allergan 88
Allergan to Enter into Partnership with Target PharmaSolutions 89
Allergan Enters into Agreement with Novartis 90
Allergan Pharma Enters into Research Agreement with Editas Medicine 91
Gedeon Richter Enters into Distribution Agreement with Allergan 92
T2 Biosystems Enters into Agreement with Allergan 93
Amgen Enters into Agreement with Allergan 94
Allergan Enters into Co-Development Agreement with AstraZeneca 95
Galderma Enters into Agreement with ZELTIQ Aesthetics 96
Allergan Enters into Agreement with Rugen Therapeutics 97
Allergan Enters into Research Agreement with Humana 98
NuMedii Enters into Research Agreement with Allergan 99
Aptinyx to Enter into Research Partnership with Allergan 100
Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 101
Molecular Partners Reinforces Partnership with Allergan 102
Allergan Enters into Distribution Agreement with WhanIn Pharma 103
Particle Sciences Enters Into Co-Development Agreement With Actavis 104
Voyant Biotherapeutics Enters Into R&D Agreement With Allergan For Ocular Disease 105
Merrimack Pharma Amends Co-Development Agreement With Actavis 106
Amerigen Pharma Enters Into Co-Development Agreement With Forest Labs For Specialty Generic Products 107
Actavis Enters Into Co-Marketing Agreement With Valeant Pharma For Zovirax Ointment 108
Actavis Enters Into Co-Promotion Agreement With Valeant Pharma For Zovirax Cream 109
Valeant Pharma Enters Into Co-Promotion Agreement With Actavis For Cordran Tape 110
Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 111
Glenmark Pharma Enters Into Co-Development Agreement With Forest Labs To Develop mPGES-1 Inhibitors 112
Skinmedica Enters Into R&D Agreement With Massachusetts General Hospital 113
Allergan Enters Into Co-Development Agreement With Molecular Partners 114
Forest Labs Enters Into Co-Development Agreement With Nabriva Therapeutics For BC-3781 115
American Medical Systems Enters Into Co-Development Agreement With Allergan 116
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 117
ZELTIQ Aesthetics Enters Into Co-Development Agreement With Massachusetts General Hospital 118
Amgen Enters Into Co-Development Agreement With Watson For Generic Cancer Drugs 119
ExonHit Extends Co-Development Agreement With Allergan 121
ACADIA Pharma Extends Drug Discovery Collaboration With Allergan 122
Allergan Enters Into Co-Promotion Agreement With MAP Pharma 123
Merger 124
Regado Biosciences Merges with Tobira Therapeutics 124
Licensing Agreements 126
Syndax Pharma Enters into Licensing Agreement with Vitae Pharma 126
Allergan Enters into Licensing Agreement with Saint Regis Mohawk Tribe 127
Allergan Enters into Licensing Agreement with Assembly Biosciences 128
Allergan Enters into Licensing Agreement with UroGen Pharma 130
Allergan Enters into Licensing Agreement with AstraZeneca 131
Cardiome Enters into Licensing Agreement with Allergan for XYDALBA 132
Dong-A Enters into Licensing Agreement with Tobira Therapeutics for Cenicriviroc 133
Allergan Amends Licensing Agreement with Heptares Therapeutics 134
Rhythm Pharma Enters into Licensing Agreement with Camurus 135
Allergan Enters into Licensing Agreement with Mimetogen Pharma 136
Allergan Enters into Licensing Agreement with Almirall for Constella 137
Apricus Biosciences Enters into Licensing Agreement with Allergan 138
Allergan Enters into Licensing Agreement with Merck 139
Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 140
Kythera Biopharma Enters into Licensing Agreement with University of Pennsylvania 141
Durata Therapeutics Enters into Licensing Agreement with Angelini for Dalvance 142
Allergan Enters Into Licensing Agreement With Medytox For Neurotoxin Product 144
Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 145
Forest Labs Enters Into Licensing Agreement With Adamas Pharma For CNS Drug 146
Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 147
RetroSense Therapeutics Enters into Licensing Agreement with University of California San Diego 148
Angelini Enters into Licensing Agreement with Allergan 149
Tobira Therapeutics Enters into Licensing Agreement with Dong-A for Evogliptin 150
Forest Labs Amends Licensing Agreement With moksha8 For Viibryd 151
InnoCore Enters Into Licensing Agreement With Allergan 152
Actavis Enters Into Licensing Agreement With Purdue Pharma For Generic OxyContin 153
RetroSense Therapeutics to Enter into Licensing Agreement with Massachusetts General Hospital 154
Topokine Therapeutics Enters into Licensing Agreement with University of Bristol 155
Almirall Enters Into Licensing Agreement With Forest Labs For Aclidinium bromide 156
Watson Pharma Enters Into Licensing Agreement With moksha8 Pharma For Five Generic Central Nervous System Products 157
Forest Labs Enters Into Licensing Agreement With moksha8 For Viibryd 158
Almirall Enters Into Licensing Agreement With Forest Labs For Linaclotide 159
Allergan Enters Into Licensing Agreement With Molecular Partners 160
Furiex Pharma Enters Into Licensing Agreement With Menarini Group For Priligy 161
Synthon Enters Into Licensing Agreement With Amgen And Watson Pharma For Trastuzumab 163
QrxPharma Enters Into Licensing Agreement With Actavis For MoxDuo IR 165
Furiex Enters Into Licensing Agreement With Janssen Pharmaceutica For MuDelta 167
RetroSense Therapeutics Enters Into Licensing Agreement With Wayne State University 168
Watson Pharma Enters Into Licensing Agreement With Antares Pharma For Anturol 169
Allergan Enters Into Licensing Agreement With Molecular Partners For MP0112 170
Durata Therapeutics Enters Into Licensing Agreement For Dalbavancin 171
Furiex Pharma Enters Into Licensing Agreement With Janssen Pharmaceutica For JNJ-Q2 172
Indoco Remedies Extends Licensing Agreement With Watson Pharma For Sterile Products 173
Biovail Labs Enters Into Licensing Agreement With Allergan For Aczone 174
Equity Offering 175
Vitae Pharma Raises USD35 Million in Public Offering of Shares 175
Aptinyx Spin Off from Naurex 177
Tobira Therapeutics Withdraws Registration Statement for Private Placement of Shares for up to USD40 Million 178
Tobira Therapeutics Raises USD27 Million in Private Placement of Shares 179
Anterios Postpones IPO for up to USD54.6 Million 180
Kythera Biopharma Raises USD143.8 Million in Public Offering of Shares 181
Actavis Raises USD5.06 Billion in Public Offering of Preferred Shares 183
Actavis Raises USD4.18 Billion in Public Offering of Shares 185
Vitae Pharma Raises USD41 Million in Public Offering of Shares 187
Vitae Pharmaceuticals Completes Exercise of Underwriter’s Over Allotment Option for IPO for USD63.3 Million 189
Tobira Therapeutics Withdraws IPO 191
Regado Biosciences Completes Public Offering Of Shares For US$60 Million 193
Regado Biosciences Completes Private Placement Of Shares For US$20 Million 195
Furiex Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 196
Kythera Biopharma Completes Underwriters’ Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For US$133.5 Million 197
Regado Biosciences Completes Underwriters’ Exercise Of Over-Allotment Option For IPO For US$43 Million 199
Durata Therapeutics Completes Public Offering Of Shares For US$58 Million 201
Kythera Biopharma Completes Underwriters’ Exercise Of Over-Allotment Option For US$81 Million 203
MAP Pharma Completes Public Offering Of Common Stock For US$60 Million 205
Forest Labs Plans Rights Offering Of Common Stock 206
Durata Therapeutics Completes IPO For US$78 Million 207
Debt Offering 209
Allergan Raises USD817.8 Million in Public Offering of 0.5% Notes Due 2021 209
Allergan Raises USD599.7 Million in Public Offering of 2.125% Notes Due 2029 210
Allergan Raises USD763.3 Million in Public Offering of Notes Due 2019 211
Allergan Raises USD763.3 Million in Public Offering of 1.25% Notes Due 2024 212
Tobira Therapeutics Raises USD13 Million in Private Placement of Notes 213
Actavis Raises USD2.5 Billion in Public Offering of Senior Notes Due 2045 214
Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2016 216
Actavis Raises USD4 Billion in Public Offering of Senior Notes Due 2025 218
Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2020 220
Actavis Raises USD1 Billion in Public Offering of Senior Notes Due 2017 222
Actavis Raises USD3 Billion in Public Offering of Senior Notes Due 2022 224
Actavis Raises USD3.5 Billion in Public Offering of Senior Notes Due 2020 226
Actavis Raises USD2.5 Billion in Public Offering of Senior Notes Due 2035 228
Actavis Raises USD3 Billion in Public Offering of Senior Notes Due 2018 230
Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2018 232
Forest Lab Completes Private Placement Of Notes Due 2021 For US$750 Million 234
Forest Lab Completes Private Placement Of Notes Due 2019 For US$1.05 Billion 235
Forest Labs Completes Private Placement Of Notes Due 2021 For US$1.2 Billion 236
Durata Therapeutics Completes First Tranche Of Private Placement Of Debt Securities For US$25 Million 237
Watson Pharma Completes Public Offering Of Notes Due 2022 For US$1.7 Billion 238
Watson Pharma Completes Public Offering Of Notes Due 2017 For US$1.2 Billion 240
Watson Pharma Completes Public Offering Of Notes Due 2042 For US$1 Billion 242
Asset Transactions 244
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 244
Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million 246
Teva Pharma Acquires Generics Drug Business from Allergan for USD39 Billion 248
Ropack Acquires Two Pharma Facilities in Long Island, New York from Forest Labs 250
AstraZeneca Acquires Respiratory Drug Business from Actavis in US and Canada 251
Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 252
Mithra Pharma Acquires Women Health Portfolio from Uteron Pharma 253
Royalty Pharma Completes Acquisition of Royalties on Alogliptin and Priligy from Forest Labs for USD415 Million 254
Impax Labs Acquires Two Generic Products from Actavis 255
G&W Labs Acquires Facility in Lincoln County, North Carolina from Actavis 256
Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For US$40.8 Million 257
Mayne Pharma Acquires Brands And Related Assets For Forest Labs For US$12 Million 259
Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To US$110 Million 260
Amneal Pharma Acquires Four Generic Products from Actavis for USD10 Million 262
Sandoz Completes Acquisition Of Four Generic Products From Watson Pharma And Actavis 264
Par Pharma Completes Acquisition Of Generic Products From Watson Pharma And Actavis 265
Harvard Drug Group Completes Acquisition Of Rugby OTC Portfolio Of Watson Pharma For US$117 Million 267
Acquisition 269
Allergan to Acquire Repros Therapeutics in Tender Offer 269
Allergan to Sell 10% Stake in Teva Pharma 271
Paratek Pharma May Sell Itself 272
Allergan Enters into Option Arrangement to Acquire Lysosomal Therapeutics 274
Allergan Acquires Motus Therapeutics 275
Allergan Acquires Chase Pharma 277
Allergan Acquires Tobira Therapeutics in Tender Offer 278
Allergan Acquires Vitae Pharma in Tender Offer 280
Teva Pharma Acquires Anda from Allergan for USD500 Million 282
Allergan Acquires ForSight VISION5 283
Allergan Acquires Akarna Therapeutics 284
Allergan Acquires RetroSense Therapeutics 285
Carl Icahn Acquires Stake in Allergan 286
Allergan Acquires Topokine Therapeutics 287
Allergan Acquires Anterios 288
Allergan Acquires Kythera Biopharma for USD2.1 Billion 289
Allergan Acquires Naurex for USD560 Million 291
Actavis Acquires Auden Mckenzie for USD458 Million 292
Actavis Acquires Allergan for USD70.5 Billion 293
Actavis May Acquire Almirall 295
Actavis Acquires Durata Therapeutics for USD675 Million in Tender Offer 296
Pfizer May Acquire Actavis 298
Forest Labs Completes Acquisition of Furiex Pharma 299
Actavis Completes Acquisition of Forest Labs for USD28 Billion 301
Actavis Acquires Silom Medical For US$100 Million 303
Forest Lab Completes Acquisition Of Aptalis Pharma From TPG Capital For US$2.9 Billion 304
Zhejiang Chiral Medicine Chemicals To Acquire Stake In Actavis (Foshan) Pharma From Actavis 306
AstraZeneca Rumored To Acquire Forest Labs For US$15 Billion 307
Actavis Completes Acquisition Of Warner Chilcott For US$8.5 Billion 308
Actavis Completes Acquisition Of Remaining 26.7% Stake In Zdravlje For Up To US$9.1 Million 311
Allergan Completes Acquisition Of MAP Pharma For US$958 Million 312
Watson Pharma Acquires Uteron Pharma, Women’s Health Company, For Up To US$305 Million 314
Allergan Completes Acquisition Of SkinMedica, Skin Products Maker, For US$350 Million 316
Watson Pharma Completes Acquisition Of Actavis Group For US$5.92 Billion 318
Watson Pharma Sells Minority Stake In moksha8 Pharma For US$47 Million 320
Watson Pharma Acquires Ascent Pharmahealth From Strides Arcolab And Dennis Bastas For US$394 Million 321
SkinMedica Acquires Colorescience, Maker Of Skincare Products 323
Allergan Completes Acquisition Of Vicept Therapeutics 324
High River Acquires 6.5% Stake In Forest Labs 325
Watson Pharma Acquires Specifar Pharma 326
Forest Labs Completes Acquisition Of Clinical Data 328
Allergan Plc – Key Competitors 331
Allergan Plc – Key Employees 332
Allergan Plc – Locations And Subsidiaries 333
Head Office 333
Other Locations & Subsidiaries 333
Recent Developments 341
Strategy And Business Planning 341
Aug 09, 2016: EDA Board Acts to Encourage Global Pharmaceutical Company Allergan to Expand in New Jersey 341
Apr 25, 2016: Allergan Breaks Ground on $200 Million Waco Facility Expansion 342
Financial Announcements 343
Nov 01, 2017: Allergan Reports Solid Top-Line Execution in Third Quarter 2017 with 11% Increase in GAAP Net Revenues to $4.03 Billion 343
Aug 03, 2017: Allergan Reports Continued Strong Execution in Second Quarter 2017 with 9% Increase in GAAP Net Revenues to $4.0 Billion 347
May 09, 2017: Allergan Reports Solid Start to 2017 with 5% Increase in First Quarter GAAP Net Revenues to $3.6 Billion 351
Feb 08, 2017: Allergan Reports Strong 2016 Finish with 7% Increase in GAAP Net Revenues to $3.9 Billion in Fourth Quarter 2016 355
Nov 02, 2016: Allergan Reports Third Quarter 2016 Continuing Operations Performance with GAAP Net Revenues of $3.6 Billion; Announces Accelerated Share Repurchase, Initiation of Cash Dividend 359
Aug 08, 2016: Allergan Reports Strong Second Quarter 2016 Continuing Operations Performance with Net Revenues of $3.7 Billion 363
May 10, 2016: Allergan Reports Strong First Quarter 2016 Continuing Operations Performance with 48% Increase in Net Revenue to $3.8 Billion and 15% Growth in Non-GAAP Diluted EPS to $3.04 367
Feb 22, 2016: Allergan Reports Exceptional Fourth Quarter 2015 Continuing Operations Performance with 74% Increase in Net Revenue to $4.2 Billion and 33% Growth in Non-GAAP Diluted EPS to $3.41 370
Corporate Communications 373
Sep 25, 2017: Allergan Announces Tessa Hilado, Executive Vice President and Chief Financial Officer, to Retire from Company 373
Sep 11, 2017: The Allergan Foundation to Donate $150,000 to Support Hurricane Irma Relief Efforts 374
Jul 19, 2017: Joseph H. Boccuzi Appointed to Allergan Board of Directors 375
Feb 27, 2017: Lisa DeFrancesco, Vice President of Investor Relations, to Leave Allergan 376
Nov 21, 2016: AstraZeneca’s MedImmune completes licensing agreement with Allergan for MEDI2070 377
Nov 14, 2016: Adriane M. Brown to Join Allergan Board of Directors 378
Oct 26, 2016: Allergan Announces Changes to Board Leadership 379
Oct 14, 2016: Allergan’s Belkyra medicine receives Swedish approval to treat double chin 380
Feb 08, 2016: Pfizer Names Executive Leadership Team for Combined Organization Upon Close of Proposed Allergan Transaction 381
Legal and Regulatory 382
Sep 11, 2017: Imprimis Releases Statement Regarding Allergan Lawsuit 382
Sep 07, 2017: Allergan Files Suits Against Imprimis Pharmaceuticals Prescriber’s Choice and Sincerus Florida 383
May 31, 2017: Attorney General DeWine Files Lawsuit Against Opioid Manufacturers for Fraudulent Marketing; Fueling Opioid Epidemic 384
Mar 30, 2016: Pfizer and Allergan Receive Request for Additional Information from Federal Trade Commission Regarding Proposed Combination 385
Government and Public Interest 386
Jan 23, 2017: Allergan Continues Commitment to Future of Headache Medicine with Educational Grants for Young Neurologists and Research Scientists 386
Product News 387
11/11/2016: Allergan Shows Strong Presence at the AASLD Liver Meeting with Data in Poster Sessions and an Oral Plenary Presentation 387
09/07/2016: Tobira Therapeutics Announces Appointment of Dr. Laurent Fischer as Industry Co-chair of the Liver Forum Steering Committee 388
08/10/2016: RetroSense Therapeutics Completes Low Dose Cohort in Clinical Trial of Novel Gene Therapy Application of Optogenetics 389
07/21/2016: Aptalis Pharma receives CHMP positive opinion on Truberzi (eluxadoline) for the treatment of Irritable Bowel Syndrome 390
06/16/2016: Tobira’s Cenicriviroc Shown to Reduce Liver Injury in Independent Research Published in the Journal Hepatology 391
06/06/2016: Vitae Pharmaceuticals Announces Appointment of Carole Sable, M.D., as Chief Medical Officer 392
06/06/2016: Chase Pharmaceuticals Continues to Build Its Senior Leadership Team with Appointment of Two Healthcare Industry Veterans 393
05/05/2016: Glaucoma Drug-Dispensing Eye Insert Shows Promise as New Option for Patients Struggling to Take Daily Prescription Eye Drops 394
05/05/2016: RetroSense Therapeutics to Highlight Contributions to Gene Therapy Research in Upcoming Conferences 395
05/03/2016: Allergan Presents New Data on LiRIS 400 mg at the American Urological Association Meeting in San Diego 396
05/01/2017: Allergan Announces Presentation on Cenicriviroc at Digestive Disease Week 2017 397
04/21/2016: Tobira Announces Upcoming Presentations on Biomarkers for NASH at Two Scientific Meetings 398
04/08/2016: Allergan To Present Data on DALVANCE (dalbavancin) at ECCMID 2016 399
Product Approvals 400
Jul 19, 2017: Investigational New Drug Application for RTGel in Combination with BOTOX for the Treatment of Overactive Bladder Submitted to FDA by Allergan 400
Jan 29, 2016: Allergan’s Rapastinel Receives FDA Breakthrough Therapy Designation for Adjunctive Treatment of Major Depressive Disorder 401
Jan 21, 2016: Allergan Announces FDA Approval of Updated Label for New Dosing Regimen for DALVANCE (dalbavancin) 402
Jan 07, 2016: Tobira Therapeutics Announces Initiation of Program to Evaluate Cenicriviroc for the Treatment of Primary Sclerosing Cholangitis 403
Clinical Trials 404
Oct 20, 2016: Tobira Therapeutics Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting 404
Oct 03, 2016: Tobira Therapeutics Announces Presentations Related to Cenicriviroc’s Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting 406
Sep 12, 2016: Tobira Therapeutics Announces Initiation of Phase 1 Combination Study of Cenicriviroc and Evogliptin 407
Jul 27, 2016: Chase Pharmaceuticals Presents Phase 2 Results for CPC-201 at 2016 Alzheimer’s Association International Conference 408
Jul 25, 2016: Tobira Therapeutics Announces Clinically and Statistically Significant Improvement in Liver Fibrosis From Phase 2b CENTAUR NASH Trial at One Year 409
Jun 27, 2016: Tobira’s Cenicriviroc Reduces Inflammation and Fibrosis in Animal Models of Chronic Liver and Kidney Disease Including NASH 411
May 13, 2016: Tobira Therapeutics Announces Publication of Phase 1 Study Results Showing Cenicriviroc Safety in Cirrhotic Patients 412
May 02, 2016: Tobira Announces Interim 12-week Results from the ORION Study 413
Apr 04, 2016: Motus Completes Enrollment of Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis 415
Apr 04, 2016: Motus Presents Clinical Proof-of-Concept Results for Relamorelin in the Treatment of Anorexia 416
Mar 16, 2016: Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe Psoriasis 417
Mar 09, 2016: Tobira Therapeutics Announces Publication of CENTAUR Phase 2b Study Design and Rationale in Contemporary Clinical Trials 418
Feb 09, 2016: Tobira Therapeutics Completes Patient Recruitment for ORION Phase 2a Study of Cenicriviroc in Obese Patients with Suspected Fatty Liver Disease 419
Jan 21, 2016: VIBERZI (eluxadoline) Phase III Trial Results Published in The New England Journal of Medicine 420
Jan 19, 2016: Rapastinel (GLYX-13) Shown to Improve Ketamine or PCP-Induced Cognitive Impairment in Mice 421
Other Significant Developments 422
Sep 25, 2017: New Study Showcases Economic Impact of Allergan Operations on French Economy 422
Sep 12, 2017: Allergan Launches New Brilliant Distinctions Patient Loyalty Program 423
Oct 16, 2016: Allergan Demonstrates Ongoing Commitment to Irritable Bowel Syndrome (IBS) with Development of IBS CounSEL 424
Oct 05, 2016: New Study Showcases Economic Impact of Allergan’s Operations on New Jersey Economy 425
Appendix 427
Methodology 427
About GlobalData 427
Contact Us 427
Disclaimer 427

List of Tables
Allergan Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 15
Allergan Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 16
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 17
Allergan Plc, Deals By Therapy Area, 2011 to YTD 2017 18
Allergan Plc, Medical Devices Deals, 2011 to YTD 2017 20
Allergan Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 21
Allergan Acquires Rights to LiRIS from TARIS Biomedical for USD588 Million 35
Actavis Acquires Four Generic Products From Akorn And Hi-Tech Pharmacal 36
Actavis Acquires Worldwide Rights To Albaconazole From Palau Pharma 38
Actavis Acquires Worldwide Rights To Metronidazole 1.3% Vaginal Gel From Valeant Pharma For US$55 Million 39
Furiex Pharma Acquires Priligy From Janssen Pharmaceutica And Alza 40
Watson Pharma Acquires Generic Pharma Products From Perrigo 41
Forest Labs Acquires Worldwide Rights Of Azimilide From Blue Ash Therapeutics 42
Allergan Acquires Distribution Business from Genop Healthcare 43
Chase Pharma Raises USD12 Million in Financing Round 44
Chase Pharma Raises Additional USD0.5 Million in Venture Financing 45
Akarna Therapeutics Raises USD15 Million in Series B Financing 46
Rhythm Pharma Raises Additional USD15 Million in Series A Financing Round 47
RetroSense Therapeutics Raises USD6 Million in Series B Financing Round 48
Chase Pharma Raises USD3 Million in Venture Financing 49
RetroSense Therapeutics Raises USD6 Million in Series A Financing 50
Naurex Raises USD80 Million in Series C Venture Financing 51
Colorescience Raises USD15 Million in Series B Venture Financing 53
Chase Pharma Raises USD21 Million in Series B Financing 54
Naurex Raises US$25 Million In Venture Financing 55
Topokine Therapeutics Raises Funds Through Venture Financing 57
Rhythm Holding Raises US$11 Million In Venture Financing 58
Colorescience Raises US$10 Million In Series A Financing 59
Anterios Raises US$8.5 Million In Venture Financing 60
Anterios Raises US$4.7 Million In Venture Financing 61
Topokine Therapeutics Raises Funds Through Venture Financing 62
Colorescience Raises US$15 Million In Venture Financing 63
Regado Biosciences Raises US$51 Million In Series E Financing 64
Naurex Raises US$38 Million In Series B Financing 66
Rhythm Pharma Raises US$33 Million In Series B Financing 68
Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 70
Rhythm Pharma Raises US$9.5 Million In Venture Financing 71
Uteron Pharma Raises US$10.4 Million In Venture Financing 72
Regado Biosciences Raises US$6.8 Million In Venture Financing 73
Motus Therapeutics Secures USD25 Million in Series B Round of Venture Funding 74
Uteron Pharma Raises US$19 Million In Venture Financing 75
SkinMedica Raises US$16.8 Million In Venture Financing 76
KYTHERA BioPharma Secures US$37.42 Million In Series D Financing Round 77
Anterios Secures US$3.1 Million In Venture Financing 79
Regado Biosciences Secures US$11.6 Million In Financing 80
Naurex Secures US$18 Million In Series A Financing Round 81
RetroSense Therapeutics Secures US$0.07 Million In Venture Financing 83
Chase Pharma Secures US$1.2 Million In Venture Financing 84
TPG Capital Acquires Aptalis Pharma from Actavis 85
VMG Partners Invests In Colorescience 86
SRIW Invests US$2 Million In Uteron Pharma 87
Lyndra Enters into Agreement with Allergan 88
Allergan to Enter into Partnership with Target PharmaSolutions 89
Allergan Enters into Agreement with Novartis 90
Allergan Pharma Enters into Research Agreement with Editas Medicine 91
Gedeon Richter Enters into Distribution Agreement with Allergan 92
T2 Biosystems Enters into Agreement with Allergan 93
Amgen Enters into Agreement with Allergan 94
Allergan Enters into Co-Development Agreement with AstraZeneca 95
Galderma Enters into Agreement with ZELTIQ Aesthetics 96
Allergan Enters into Agreement with Rugen Therapeutics 97
Allergan Enters into Research Agreement with Humana 98
NuMedii Enters into Research Agreement with Allergan 99
Aptinyx to Enter into Research Partnership with Allergan 100
Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 101
Molecular Partners Reinforces Partnership with Allergan 102
Allergan Enters into Distribution Agreement with WhanIn Pharma 103
Particle Sciences Enters Into Co-Development Agreement With Actavis 104
Voyant Biotherapeutics Enters Into R&D Agreement With Allergan For Ocular Disease 105
Merrimack Pharma Amends Co-Development Agreement With Actavis 106
Amerigen Pharma Enters Into Co-Development Agreement With Forest Labs For Specialty Generic Products 107
Actavis Enters Into Co-Marketing Agreement With Valeant Pharma For Zovirax Ointment 108
Actavis Enters Into Co-Promotion Agreement With Valeant Pharma For Zovirax Cream 109
Valeant Pharma Enters Into Co-Promotion Agreement With Actavis For Cordran Tape 110
Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 111
Glenmark Pharma Enters Into Co-Development Agreement With Forest Labs To Develop mPGES-1 Inhibitors 112
Skinmedica Enters Into R&D Agreement With Massachusetts General Hospital 113
Allergan Enters Into Co-Development Agreement With Molecular Partners 114
Forest Labs Enters Into Co-Development Agreement With Nabriva Therapeutics For BC-3781 115
American Medical Systems Enters Into Co-Development Agreement With Allergan 116
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 117
ZELTIQ Aesthetics Enters Into Co-Development Agreement With Massachusetts General Hospital 118
Amgen Enters Into Co-Development Agreement With Watson For Generic Cancer Drugs 119
ExonHit Extends Co-Development Agreement With Allergan 121
ACADIA Pharma Extends Drug Discovery Collaboration With Allergan 122
Allergan Enters Into Co-Promotion Agreement With MAP Pharma 123
Regado Biosciences Merges with Tobira Therapeutics 124
Syndax Pharma Enters into Licensing Agreement with Vitae Pharma 126
Allergan Enters into Licensing Agreement with Saint Regis Mohawk Tribe 127
Allergan Enters into Licensing Agreement with Assembly Biosciences 128
Allergan Enters into Licensing Agreement with UroGen Pharma 130
Allergan Enters into Licensing Agreement with AstraZeneca 131
Cardiome Enters into Licensing Agreement with Allergan for XYDALBA 132
Dong-A Enters into Licensing Agreement with Tobira Therapeutics for Cenicriviroc 133
Allergan Amends Licensing Agreement with Heptares Therapeutics 134
Rhythm Pharma Enters into Licensing Agreement with Camurus 135
Allergan Enters into Licensing Agreement with Mimetogen Pharma 136
Allergan Enters into Licensing Agreement with Almirall for Constella 137
Apricus Biosciences Enters into Licensing Agreement with Allergan 138
Allergan Enters into Licensing Agreement with Merck 139
Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 140
Kythera Biopharma Enters into Licensing Agreement with University of Pennsylvania 141
Durata Therapeutics Enters into Licensing Agreement with Angelini for Dalvance 142
Allergan Enters Into Licensing Agreement With Medytox For Neurotoxin Product 144
Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 145
Forest Labs Enters Into Licensing Agreement With Adamas Pharma For CNS Drug 146
Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 147
RetroSense Therapeutics Enters into Licensing Agreement with University of California San Diego 148
Angelini Enters into Licensing Agreement with Allergan 149
Tobira Therapeutics Enters into Licensing Agreement with Dong-A for Evogliptin 150
Forest Labs Amends Licensing Agreement With moksha8 For Viibryd 151
InnoCore Enters Into Licensing Agreement With Allergan 152
Actavis Enters Into Licensing Agreement With Purdue Pharma For Generic OxyContin 153
RetroSense Therapeutics to Enter into Licensing Agreement with Massachusetts General Hospital 154
Topokine Therapeutics Enters into Licensing Agreement with University of Bristol 155
Almirall Enters Into Licensing Agreement With Forest Labs For Aclidinium bromide 156
Watson Pharma Enters Into Licensing Agreement With moksha8 Pharma For Five Generic Central Nervous System Products 157
Forest Labs Enters Into Licensing Agreement With moksha8 For Viibryd 158
Almirall Enters Into Licensing Agreement With Forest Labs For Linaclotide 159
Allergan Enters Into Licensing Agreement With Molecular Partners 160
Furiex Pharma Enters Into Licensing Agreement With Menarini Group For Priligy 161
Synthon Enters Into Licensing Agreement With Amgen And Watson Pharma For Trastuzumab 163
QrxPharma Enters Into Licensing Agreement With Actavis For MoxDuo IR 165
Furiex Enters Into Licensing Agreement With Janssen Pharmaceutica For MuDelta 167
RetroSense Therapeutics Enters Into Licensing Agreement With Wayne State University 168
Watson Pharma Enters Into Licensing Agreement With Antares Pharma For Anturol 169
Allergan Enters Into Licensing Agreement With Molecular Partners For MP0112 170
Durata Therapeutics Enters Into Licensing Agreement For Dalbavancin 171
Furiex Pharma Enters Into Licensing Agreement With Janssen Pharmaceutica For JNJ-Q2 172
Indoco Remedies Extends Licensing Agreement With Watson Pharma For Sterile Products 173
Biovail Labs Enters Into Licensing Agreement With Allergan For Aczone 174
Vitae Pharma Raises USD35 Million in Public Offering of Shares 175
Aptinyx Spin Off from Naurex 177
Tobira Therapeutics Withdraws Registration Statement for Private Placement of Shares for up to USD40 Million 178
Tobira Therapeutics Raises USD27 Million in Private Placement of Shares 179
Anterios Postpones IPO for up to USD54.6 Million 180
Kythera Biopharma Raises USD143.8 Million in Public Offering of Shares 181
Actavis Raises USD5.06 Billion in Public Offering of Preferred Shares 183
Actavis Raises USD4.18 Billion in Public Offering of Shares 185
Vitae Pharma Raises USD41 Million in Public Offering of Shares 187
Vitae Pharmaceuticals Completes Exercise of Underwriter's Over Allotment Option for IPO for USD63.3 Million 189
Tobira Therapeutics Withdraws IPO 191
Regado Biosciences Completes Public Offering Of Shares For US$60 Million 193
Regado Biosciences Completes Private Placement Of Shares For US$20 Million 195
Furiex Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 196
Kythera Biopharma Completes Underwriters’ Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For US$133.5 Million 197
Regado Biosciences Completes Underwriters' Exercise Of Over-Allotment Option For IPO For US$43 Million 199
Durata Therapeutics Completes Public Offering Of Shares For US$58 Million 201
Kythera Biopharma Completes Underwriters' Exercise Of Over-Allotment Option For US$81 Million 203
MAP Pharma Completes Public Offering Of Common Stock For US$60 Million 205
Forest Labs Plans Rights Offering Of Common Stock 206
Durata Therapeutics Completes IPO For US$78 Million 207
Allergan Raises USD817.8 Million in Public Offering of 0.5% Notes Due 2021 209
Allergan Raises USD599.7 Million in Public Offering of 2.125% Notes Due 2029 210
Allergan Raises USD763.3 Million in Public Offering of Notes Due 2019 211
Allergan Raises USD763.3 Million in Public Offering of 1.25% Notes Due 2024 212
Tobira Therapeutics Raises USD13 Million in Private Placement of Notes 213
Actavis Raises USD2.5 Billion in Public Offering of Senior Notes Due 2045 214
Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2016 216
Actavis Raises USD4 Billion in Public Offering of Senior Notes Due 2025 218
Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2020 220
Actavis Raises USD1 Billion in Public Offering of Senior Notes Due 2017 222
Actavis Raises USD3 Billion in Public Offering of Senior Notes Due 2022 224
Actavis Raises USD3.5 Billion in Public Offering of Senior Notes Due 2020 226
Actavis Raises USD2.5 Billion in Public Offering of Senior Notes Due 2035 228
Actavis Raises USD3 Billion in Public Offering of Senior Notes Due 2018 230
Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2018 232
Forest Lab Completes Private Placement Of Notes Due 2021 For US$750 Million 234
Forest Lab Completes Private Placement Of Notes Due 2019 For US$1.05 Billion 235
Forest Labs Completes Private Placement Of Notes Due 2021 For US$1.2 Billion 236
Durata Therapeutics Completes First Tranche Of Private Placement Of Debt Securities For US$25 Million 237
Watson Pharma Completes Public Offering Of Notes Due 2022 For US$1.7 Billion 238
Watson Pharma Completes Public Offering Of Notes Due 2017 For US$1.2 Billion 240
Watson Pharma Completes Public Offering Of Notes Due 2042 For US$1 Billion 242
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 244
Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million 246
Teva Pharma Acquires Generics Drug Business from Allergan for USD39 Billion 248
Ropack Acquires Two Pharma Facilities in Long Island, New York from Forest Labs 250
AstraZeneca Acquires Respiratory Drug Business from Actavis in US and Canada 251
Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 252
Mithra Pharma Acquires Women Health Portfolio from Uteron Pharma 253
Royalty Pharma Completes Acquisition of Royalties on Alogliptin and Priligy from Forest Labs for USD415 Million 254
Impax Labs Acquires Two Generic Products from Actavis 255
G&W Labs Acquires Facility in Lincoln County, North Carolina from Actavis 256
Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For US$40.8 Million 257
Mayne Pharma Acquires Brands And Related Assets For Forest Labs For US$12 Million 259
Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To US$110 Million 260
Amneal Pharma Acquires Four Generic Products from Actavis for USD10 Million 262
Sandoz Completes Acquisition Of Four Generic Products From Watson Pharma And Actavis 264
Par Pharma Completes Acquisition Of Generic Products From Watson Pharma And Actavis 265
Harvard Drug Group Completes Acquisition Of Rugby OTC Portfolio Of Watson Pharma For US$117 Million 267
Allergan to Acquire Repros Therapeutics in Tender Offer 269
Allergan to Sell 10% Stake in Teva Pharma 271
Paratek Pharma May Sell Itself 272
Allergan Enters into Option Arrangement to Acquire Lysosomal Therapeutics 274
Allergan Acquires Motus Therapeutics 275
Allergan Acquires Chase Pharma 277
Allergan Acquires Tobira Therapeutics in Tender Offer 278
Allergan Acquires Vitae Pharma in Tender Offer 280
Teva Pharma Acquires Anda from Allergan for USD500 Million 282
Allergan Acquires ForSight VISION5 283
Allergan Acquires Akarna Therapeutics 284
Allergan Acquires RetroSense Therapeutics 285
Carl Icahn Acquires Stake in Allergan 286
Allergan Acquires Topokine Therapeutics 287
Allergan Acquires Anterios 288
Allergan Acquires Kythera Biopharma for USD2.1 Billion 289
Allergan Acquires Naurex for USD560 Million 291
Actavis Acquires Auden Mckenzie for USD458 Million 292
Actavis Acquires Allergan for USD70.5 Billion 293
Actavis May Acquire Almirall 295
Actavis Acquires Durata Therapeutics for USD675 Million in Tender Offer 296
Pfizer May Acquire Actavis 298
Forest Labs Completes Acquisition of Furiex Pharma 299
Actavis Completes Acquisition of Forest Labs for USD28 Billion 301
Actavis Acquires Silom Medical For US$100 Million 303
Forest Lab Completes Acquisition Of Aptalis Pharma From TPG Capital For US$2.9 Billion 304
Zhejiang Chiral Medicine Chemicals To Acquire Stake In Actavis (Foshan) Pharma From Actavis 306
AstraZeneca Rumored To Acquire Forest Labs For US$15 Billion 307
Actavis Completes Acquisition Of Warner Chilcott For US$8.5 Billion 308
Actavis Completes Acquisition Of Remaining 26.7% Stake In Zdravlje For Up To US$9.1 Million 311
Allergan Completes Acquisition Of MAP Pharma For US$958 Million 312
Watson Pharma Acquires Uteron Pharma, Women's Health Company, For Up To US$305 Million 314
Allergan Completes Acquisition Of SkinMedica, Skin Products Maker, For US$350 Million 316
Watson Pharma Completes Acquisition Of Actavis Group For US$5.92 Billion 318
Watson Pharma Sells Minority Stake In moksha8 Pharma For US$47 Million 320
Watson Pharma Acquires Ascent Pharmahealth From Strides Arcolab And Dennis Bastas For US$394 Million 321
SkinMedica Acquires Colorescience, Maker Of Skincare Products 323
Allergan Completes Acquisition Of Vicept Therapeutics 324
High River Acquires 6.5% Stake In Forest Labs 325
Watson Pharma Acquires Specifar Pharma 326
Forest Labs Completes Acquisition Of Clinical Data 328
Allergan Plc, Key Competitors 331
Allergan Plc, Key Employees 332
Allergan Plc, Other Locations 333
Allergan Plc, Subsidiaries 333

★海外企業調査レポート[Allergan Plc (AGN)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Getinge AB：企業の戦略・SWOT・財務情報
    Getinge AB - Strategy, SWOT and Corporate Finance Report Summary Getinge AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • ALK-Abello AS (ALK B)-製薬・医療分野：企業M&A・提携分析
    Summary ALK-Abello A/S (ALK) is a research-oriented pharmaceutical company, which discovers, develops and commercializes immunotherapies for allergy prevention and treatment. It also markets diagnostics and other services to allergy clinics. The company's allergy immunotherapy product portfolio incl …
  • Tp Icap Plc
    Tp Icap Plc - Strategy, SWOT and Corporate Finance Report Summary Tp Icap Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • International Flavors & Fragrances Inc (IFF)：企業の財務・戦略的SWOT分析
    International Flavors & Fragrances Inc (IFF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Philippine Long Distance Telephone Co (TEL)：企業の戦略的SWOT分析
    Philippine Long Distance Telephone Co (TEL) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors a …
  • Medshape Inc：医療機器：M&Aディール及び事業提携情報
    Summary Medshape Inc (MedShape), formerly MedShape Solutions Inc, is a medical device company that develops and manufactures orthopedic devices for the orthopedic healthcare markets. The company provides products such as dynanail ankle arthrodesis nail, eclipse soft tissue anchor, exoshape teno soft …
  • IAV GmbH：企業の戦略的SWOT分析
    IAV GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Syntel Inc (SYNT)：企業の財務・戦略的SWOT分析
    Syntel Inc (SYNT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Pioneer Energy Services Corp (PES)：企業の財務・戦略的SWOT分析
    Pioneer Energy Services Corp (PES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Cargolux Airlines International S.A.：企業の戦略・SWOT・財務分析
    Cargolux Airlines International S.A. - Strategy, SWOT and Corporate Finance Report Summary Cargolux Airlines International S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Oxford University Innovation Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Oxford University Innovation Ltd (Oxford University Innovation), formerly Isis Innovation Ltd a subsidiary of University of Oxford is a technology transfer university that offers academic consulting services and leads to research and education. The university offers university consulting, me …
  • Tosk Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Tosk Inc (Tosk) is a drug developing company that provides development of safety and efficacy conditions of drugs. The company discovers and develops new drugs for cancer and other conditions using non-mammalian animal species as models for human diseases. It provides optimizing marketed dru …
  • Hua Xia Bank Co., Limited ：企業の戦略・SWOT・財務情報
    Hua Xia Bank Co., Limited - Strategy, SWOT and Corporate Finance Report Summary Hua Xia Bank Co., Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Pennon Group Plc (PNN)：企業の財務・戦略的SWOT分析
    Pennon Group Plc (PNN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Vaisala oyj (VAIAS)：企業の財務・戦略的SWOT分析
    Summary Vaisala oyj (Vaisala) is a manufacturer of industrial and environmental measurement products. Its products include automatic weather stations and sensors, aviation weather systems, wireless temperature and humidity data loggers, indoor monitoring systems, weather radar products, rail weather …
  • Grupa Lotos SA (LTS)：石油・ガス：M&Aディール及び事業提携情報
    Summary Grupa Lotos S.A. (Grupa Lotos) is an integrated energy company. The company carries out various activities such as the extraction and refining of crude oil; processing of petroleum into finished products; and the wholesale and retail distribution and sale of petroleum products. Its product p …
  • Cooper Energy Ltd (COE)：企業の財務・戦略的SWOT分析
    Summary Cooper Energy Ltd (CEL) is an oil and gas exploration and production company that offers oil production programs. The company produces, and commercializes crude oil and natural gas products. It conducts exploration for oil and gas through a portfolio of prospective acreage in the Cooper, Otw …
  • AMETEK Inc (AME)：企業の財務・戦略的SWOT分析
    Summary AMETEK Inc (AMETEK) is an electronic products manufacturer. The company manufactures electronic instruments and electromechanical devices. Its product portfolio includes medical materials, motion control systems, sub assemblies and connectors, electrical cord reels, gauges, titanium alloys a …
  • OSX Brasil SA (OSXB3)：石油・ガス：M&Aディール及び事業提携情報
    Summary OSX Brasil SA (OSX), formerly EBX Brasil SA is an oil and gas company. The company provides equipment and services to operate in the naval and offshore industry. It offers integrated engineering, construction, chartering, and operation and maintenance services for oil exploration and product …
  • Arcadia Biosciences Inc (RKDA)：企業の財務・戦略的SWOT分析
    Summary Arcadia Biosciences Inc (Arcadia) is an agricultural and clean technology company that develops and commercializes agricultural products. Its major products include goodwheat branded ingredients, nutritional oils, animal nutrition and agricultural products. The company's products exhibit tra …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆